SLC5A2 and diabetes mellitus: Empagliflozin and dapagliflozin, some of the most used SGLT2 inhibitors, have been shown to substantially reduce the risk of hospitalization and mortality associated with HF, regardless of the presence of diabetes, according to clinical evidence.